Abstract: A positioning method of functional rotation center of shoulder based on rigid upper arm model includes: step 1: abstracting a human upper arm into a cylinder with FRCS as a center of top surface; step 2: determining a reference axis vector of the cylinder; step 3: determining an axis vector of the cylinder and a displacement from the reference axis vector to the axis vector; step 4: correcting a central axis direction of the cylinder; step 5: determining a height compensation of the cylinder, and positioning the FRCS. The method has higher accuracy for the positioning result of FRCS, the positioning result of FRCS has better stability relative to the upper arm and trunk, and can be used to establish a more accurate human digital dynamic model and predict more accurate human posture.

Abstract: Disclosed is a kettle-type continuous production method for glycine. The method includes: performing a hydantoin synthesis and hydrolysis reaction on glycolonitrile, ammonium carbonate, ammonium bicarbonate and water in a reactor with multiple serially connected kettles, and then purifying, concentrating, crystallizing, separating and drying the products to obtain refined glycine. The reactor with multiple serially connected kettles consists of a hydantoin synthesis section and a hydantoin hydrolysis section which are connected in sequence, the hydantoin synthesis section including a first reaction kettle group of reaction kettles with a reaction temperature of 80-100° C. and a second reaction kettle group of reaction kettles with a reaction temperature of 100-120° C.

Abstract: A detecting method and a positioning analysis method of human functional joint rotation center are provided. The detecting method of human functional joint rotation center includes: step 11: in a continuous motion, a human functional joint rotation center FCR is abstracted as a center of a flexible ball; step 12: at any moment during a test, position coordinates of the center of the ball (i.e. FCR) at the moment are determined according to position coordinates of M1, M2 and M3, and then the motion trajectory of the FCR is obtained in the continuous motion; the positioning analysis method performs positioning analysis of joint positions based on morphological parameters collected by 3D scanning. The detecting method is based on an idea of flexible ball, its operation is simple within a certain error range, and the method performs very well in the continuity of trajectory of joint.

Abstract: A detecting method and a positioning analysis method of human functional joint rotation center are provided. The detecting method of human functional joint rotation center includes: step 11: in a continuous motion, a human functional joint rotation center FCR is abstracted as a center of a flexible ball; step 12: at any moment during a test, position coordinates of the center of the ball (i.e. FCR) at the moment are determined according to position coordinates of M1, M2 and M3, and then the motion trajectory of the FCR is obtained in the continuous motion; the positioning analysis method performs positioning analysis of joint positions based on morphological parameters collected by 3D scanning. The detecting method is based on an idea of flexible ball, its operation is simple within a certain error range, and the method performs very well in the continuity of trajectory of joint.

Abstract: A positioning method of functional rotation center of shoulder based on rigid upper arm model includes: step 1: abstracting a human upper arm into a cylinder with FRCS as a center of top surface; step 2: determining a reference axis vector of the cylinder; step 3: determining an axis vector of the cylinder and a displacement from the reference axis vector to the axis vector; step 4: correcting a central axis direction of the cylinder; step 5: determining a height compensation of the cylinder, and positioning the FRCS. The method has higher accuracy for the positioning result of FRCS, the positioning result of FRCS has better stability relative to the upper arm and trunk, and can be used to establish a more accurate human digital dynamic model and predict more accurate human posture.

Abstract: The present invention provides uses of a compound represented by formula A in the preparation of drugs for treating brain glioma and particularly glioblastoma. Particularly provided are uses of the compound represented by formula A in the preparation of drugs for treating expression of specific fusion protein. By means of the technical solution of the present invention, typing of brain glioblastoma can be implemented, a drug administration can be carried out for a specific patient group, and precise treatment can be implemented.

Abstract: The present invention provides uses of a compound represented by formula A in the preparation of drugs for treating brain glioma and particularly glioblastoma. Particularly provided are uses of the compound represented by formula A in the preparation of drugs for treating expression of specific fusion protein. By means of the technical solution of the present invention, typing of brain glioblastoma can be implemented, a drug administration can be carried out for a specific patient group, and precise treatment can be implemented.

Abstract: The present invention provides deleted adenovirus vectors. The inventive adenovirus vectors carry one or more deletions in the IVa2, 100K, polymerase and/or preterminal protein sequences of the adenovirus genome. The adenoviruses may additionally contain other deletions, mutations or other modifications as well. In particular preferred embodiments, the adenovirus genome is multiply deleted, i.e., carries two or more deletions therein. The deleted adenoviruses of the invention are “propagation-defective” in that the virus cannot replicate and produce new virions in the absence of complementing function(s). Preferred adenovirus vectors of the invention carry a heterologous nucleotide sequence encoding a protein or peptide associated with a metabolic disorder, more preferably a protein or peptide associated with a lysosomal or glycogen storage disease, most preferably, a lysosomal acid ?-glucosidase. Further provided are methods for producing the inventive deleted adenovirus vectors.

Abstract: The present invention provides deleted adenovirus vectors. The inventive adenovirus vectors carry one or more deletions in the IVa2, 100 K, polymerase and/or preterminal protein sequences of the adenovirus genome. The adenoviruses may additionally contain other deletions, mutations or other modifications as well. In particular preferred embodiments, the adenovirus genome is multiply deleted, i.e., carries two or more deletions therein. The deleted adenoviruses of the invention are “propagation-defective” in that the virus cannot replicate and produce new virions in the absence of complementing function(s). Preferred adenovirus vectors of the invention carry a heterologous nucleotide sequence encoding a protein or peptide associated with a metabolic disorder, more preferably a protein or peptide associated with a lysosomal or glycogen storage disease, most preferably, a lysosomal acid ?-glucosidase. Further provided are methods for producing the inventive deleted adenovirus vectors.

Abstract: The present invention provides deleted adenovirus vectors. The inventive adenovirus vectors carry one or more deletions in the IVa2, 100K, polymerase and/or preterminal protein sequences of the adenovirus genome. The adenoviruses may additionally contain other deletions, mutations or other modifications as well. In particular preferred embodiments, the adenovirus genome is multiply deleted, i.e., carries two or more deletions therein. The deleted adenoviruses of the invention are “propagation-defective” in that the virus cannot replicate and produce new virions in the absence of complementing function(s). Preferred adenovirus vectors of the invention carry a heterologous nucleotide sequence encoding a protein or peptide associated with a metabolic disorder, more preferably a protein or peptide associated with a lysosomal or glycogen storage disease, most preferably, a lysosomal acid &agr;-glucosidase. Further provided are methods for producing the inventive deleted adenovirus vectors.

Abstract: The present invention provides deleted adenovirus vectors. The inventive adenovirus vectors carry one or more deletions in the IVa2, 100K, polymerase and/or preterminal protein sequences of the adenovirus genome. The adenoviruses may additionally contain other deletions, mutations or other modifications as well. In particular preferred embodiments, the adenovirus genome is multiply deleted, i.e., carries two or more deletions therein. The deleted adenoviruses of the invention are “propagation-defective” in that the virus cannot replicate and produce new virions in the absence of complementing function(s). Preferred adenovirus vectors of the invention carry a heterologous nucleotide sequence encoding a protein or peptide associated with a metabolic disorder, more preferably a protein or peptide associated with a lysosomal or glycogen storage disease, most preferably, a lysosomal acid &agr;-glucosidase. Further provided are methods for producing the inventive deleted adenovirus vectors.

Abstract: The present invention provides deleted adenovirus vectors. The inventive adenovirus vectors carry one or more deletions in the IVa2, 100K, polymerase and/or preterminal protein sequences of the adenovirus genome. The adenoviruses may additionally contain other deletions, mutations or other modifications as well. In particular preferred embodiments, the adenovirus genome is multiply deleted, i.e., carries two or more deletions therein. The deleted adenoviruses of the invention are “propagation-defective” in that the virus cannot replicate and produce new virions in the absence of complementing function(s). Preferred adenovirus vectors of the invention carry a heterologous nucleotide sequence encoding a protein or peptide associated with a metabolic disorder, more preferably a protein or peptide associated with a lysosomal or glycogen storage disease, most preferably, a lysosomal acid &agr;-glucosidase. Further provided are methods for producing the inventive deleted adenovirus vectors.